Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/108482
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Biomedical Engineering-
dc.creatorZhang, Z-
dc.creatorCao, C-
dc.creatorZhou, CL-
dc.creatorLi, X-
dc.creatorMiao, C-
dc.creatorShen, L-
dc.creatorSingla, RK-
dc.creatorLu, X-
dc.date.accessioned2024-08-19T01:58:41Z-
dc.date.available2024-08-19T01:58:41Z-
dc.identifier.issn1944-7124-
dc.identifier.urihttp://hdl.handle.net/10397/108482-
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.rights© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rightsThe following publication Zhang, Z., Cao, C., Zhou, C.-L., Li, X., Miao, C., Shen, L., Singla, R. K., & Lu, X. (2023). Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing. Translational Oncology, 36, 101741 is available at https://doi.org/10.1016/j.tranon.2023.101741.en_US
dc.subject5-methylcytosineen_US
dc.subjectKidney canceren_US
dc.subjectKidney renal papillary cell carcinomaen_US
dc.subjectPrognostic signatureen_US
dc.subjectRenal cell carcinomaen_US
dc.subjectTumor microenvironmenten_US
dc.subjectTumor therapyen_US
dc.titleIdentification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposingen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume36-
dc.identifier.doi10.1016/j.tranon.2023.101741-
dcterms.abstractBackground: Many studies have demonstrated the crucial roles of 5-methylcytosine (m5C) RNA methylation in cancer pathogenesis.-
dcterms.abstractMethods: Two datasets, including TCGA-KIRP and ICGC, and related clinical information were downloaded, where the expression of 13 m5C regulators was examined. We applied LASSO regression to construct a multi-m5C-regulator-based signature in the TCGA cohort, which was further validated using the ICGC cohort. Univariate and multivariate Cox regressions were applied to evaluate the independent prognostic value of our model. The differences in biological functions and immune characterizations between high and low-risk groups divided based on the risk scores were also investigated via multiple approaches, such as enrichment analyses, mutation mining, and immune scoring. Finally, the sensitivities of commonly used targeted drugs were tested, and the connectivity MAP (cMAP) was utilized to screen potentially effective molecules for patients in the high-risk group. Experimental validation was done following qPCR tests in Caki-2 and HK-2 cell lines.-
dcterms.abstractResults: 3 m5C regulators, including ALYREF, DNMT3B and YBX1, were involved in our model. Survival analysis revealed a worse prognosis for patients in the high-risk group. Cox regression results indicated our model's superior predictive performance compared to single-factor prognostic evaluation. Functional enrichment analyses indicated a higher mutation frequency and poorer tumor microenvironment of patients in the high-risk group. qPCR-based results revealed that ALYREF, DNMT3B, and YBX1 were significantly up-regulated in Caki-2 cell lines compared with HK-2 cell lines. Molecules like BRD-K72451865, Levosimendan, and BRD-K03515135 were advised by cMAP for patients in the high-risk group.-
dcterms.abstractConclusion: Our study presented a novel predictive model for KIRP prognosis. Furthermore, the results of our analysis provide new insights for investigating m5C events in KIRP pathogenesis. Graphical abstract: [Figure not available: see fulltext.]-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationTranslational oncology, Oct. 2023, v. 36, 101741-
dcterms.isPartOfTranslational oncology-
dcterms.issued2023-10-
dc.identifier.scopus2-s2.0-85166518363-
dc.identifier.eissn1936-5233-
dc.identifier.artn101741-
dc.description.validate202408 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextHealth Commission of Henan Province; 2020 Medical Science and Technology Research Plan of Henan Provinceen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
1-s2.0-S1936523323001274-main.pdf4.5 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

59
Citations as of Nov 10, 2025

Downloads

20
Citations as of Nov 10, 2025

SCOPUSTM   
Citations

7
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

5
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.